JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Hepatic cirrhosis and decompensation: Key indicators for predicting mortality risk

  • 0Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome 00185, Italy.
World Journal of Hepatology +

|

April 3, 2025

|

April 3, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Identifying patients at high risk of mortality in liver cirrhosis is crucial. Current scoring systems like MELD and Child-Pugh have limitations; incorporating body composition, especially sarcopenia, can improve prognostic assessment for liver disease patients.

Area Of Science

  • Hepatology
  • Internal Medicine
  • Clinical Nutrition

Background

  • Liver cirrhosis is the advanced stage of chronic liver disease.
  • Progression from compensated to decompensated cirrhosis significantly worsens patient prognosis.
  • Accurate risk stratification is essential for managing cirrhotic patients.

Purpose Of The Study

  • To highlight the limitations of current prognostic scores for liver cirrhosis.
  • To emphasize the prognostic significance of body composition alterations, particularly sarcopenia.
  • To advocate for the inclusion of body composition in comprehensive cirrhotic patient assessment.

Main Methods

  • Review of existing literature on liver cirrhosis prognosis.
  • Analysis of validated scoring systems (MELD, Child-Pugh).
  • Discussion of the impact of body composition and sarcopenia on outcomes.

Main Results

  • Current scores (MELD, Child-Pugh) do not fully capture prognostic factors.
  • Sarcopenia and other body composition changes are linked to increased mortality risk.
  • Body composition assessment offers complementary prognostic information.

Conclusions

  • Existing prognostic scores for liver cirrhosis are insufficient.
  • Body composition, especially sarcopenia, is a critical, underutilized prognostic indicator.
  • Integrating body composition analysis into patient assessment can enhance risk prediction and management strategies for liver cirrhosis.

Keywords:

Related Concept Videos

Esophageal Varices-II: Clinical Features and Management 01:28

31

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers 01:19

38

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

Diseases of the Liver and Gallbladder 01:26

374

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...

Blood Studies for Cardiovascular System I: Cardiac Biomarkers 01:20

71

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...